Business Wire

Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA ...
MarketWatch

Commit Biologics to present data on its Bispecific Complement Engaging (BiCE(TM)) platform at the 16th International Conference on Complement Therapeutics

The MarketWatch News Department was not involved in the creation of this content. -- Commit Biologics is pioneering a novel approach to activating the complement component of the immune system to ...
FiercePharma

Alnylam Scientists Present Pre-clinical Data with ALN-CC5, an RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases

Alnylam Scientists Present Pre-clinical Data with ALN-CC5, an RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases – New Research Presented at 6 th ...
Nature

Urinary Complement proteome strongly linked to diabetic kidney disease progression

Diabetic kidney disease (DKD) progression is not well understood. Using high-throughput proteomics, biostatistical, pathway and machine learning tools, we examine the urinary Complement proteome in ...